Morgan Lewis partner Donna Lee Yesner will present a panel on the Economic Impact of Federal Drug Discount and Rebate Programs on Biologic Products at the 2013 Bio Conference.
Ms. Yesner's panel will explore the 340B drug discount program and other federal statutory discount and rebate programs as they apply to biological products approved under the licensing authority provisions of the Public Health Service Act, and also whether these statutes differentiate between reference biological products and biosimilars. Panelists will discuss the impact mandatory discounts have on investment in R&D, and the pricing and supply of biological products from the manufacturer's perspective, in particular the impact of the 340B program through which hospitals purchase deeply discounted drugs administered in an outpatient setting, and historical experiences with low returns on injectable products contributing to a reduction in competition and supply shortages. The panel will also discuss the anti-inflation penalties under these programs and the impact they have on launch pricing decisions and discount strategies.
Tuesday, Apr 23, 2013